NICE Consultation: What the updated manual for technology appraisals means for Health Tech innovators

NICE has opened a consultation on a major update to its technology appraisal manual that could reshape how health technologies gain access to the NHS. The proposals bring medical devices, diagnostics, and digital tools closer to the “medicines-style” appraisal pathway. This is a significant signal towards a new era of parity between drugs and Med Tech.

For the medtech industry, this means higher evidence expectations, but also holds the potential for a clearer and faster route to national adoption.

From fragmented routes to a single pathway

Historically, medtech products have faced a number of potential evaluation routes. NICE’s existing programmes for diagnostics, devices and digital health technologies have offered valuable recognition but no automatic NHS funding mandate. By contrast, NICE Technology Appraisals (TAs) for medicines mandate a national NHS reimbursement requirement.

This consultation proposes to go some way towards closing that gap. Under the updated manual, selected HealthTech products could be evaluated through the TA route, creating a more coherent end-to-end process that links evidence generation, appraisal, and funding.

It also aligns with NHS England’s wider ambition for a “Rules-Based Pathway” for medtech, integrating evaluation, commissioning, and adoption for priority technologies. Together, these reforms could make medtech adoption more predictable, nationally consistent, and tied to real-world value.

Key changes proposed

The revised technology appraisal manual is expanded in both scope and expectation.

Broader coverage: the manual would explicitly include HealthTech and highly specialised technologies, bringing together previously separate processes.

Stronger scoping: topics will be more tightly defined at the outset, with early identification of evidence gaps and clear routing to the right process, from Early Value Assessment (EVA) through to full appraisal.

Higher bar for real-world evidence: NICE’s updated RWE framework raises the standard for non-randomised evidence, emphasising pre-specified protocols, data transparency, and quality assurance.

Economic rigour: Health Tech appraisals will face closer scrutiny of model quality, assumptions, and validation.

Multi-technology assessments: NICE expects comparative evaluations across products within a category, raising the bar on differentiation and pricing.

Implementation readiness: appraisals will consider workflow integration, training, data governance and monitoring, not just efficacy or cost.

This all marks a shift towards a rounded assessment of system-wide impact and readiness for scale.

The four evaluation stages

Implications for industry

The direction of travel is clear: NICE is aiming to rationalise the types of guidance and move from advisory guidance towards a structured, rules-based system tied to national priorities. For medtech companies seeking NHS market access, the implications could be significant.

Stronger evidence expectations
HealthTech developers will need to invest earlier in generating credible, transparent evidence — clinical, economic and real-world. NICE’s embrace of RWE offers flexibility, but data quality and strength of evidence in real-world settings will be closely examined.

Comparative pressure
Multi-technology assessments mean companies must demonstrate clear superiority or cost-efficiency over rival technologies, not just basic compliance or unproven assertions.

Adoption planning becomes part of evaluation
NICE will expect detailed plans for implementation including training, information governance, workflow integration and monitoring as part of the evidence package.

Closer link between evaluation and reimbursement
If a funding mandate is introduced for HealthTech appraised via the TA route, the reward could be significant: predictable access, faster scale-up, and clearer ROI for investors. But this will likely apply only to a small pilot cohort initially.

New commercial realities
The traditional expectation that medtech must be cost-saving is giving way to a more nuanced test of cost-effectiveness. This broadens eligibility for positive recommendations but demands more sophisticated modelling and transparency.

Practical takeaways for innovators

Time your approach: enter evaluation when the evidence base is credible and the comparator landscape is clear.

Design studies strategically: build evidence that can progress from EVA to full guidance or TA. Include productivity and workflow metrics alongside clinical outcomes.

Demonstrate readiness: prepare SOPs, training materials, information-governance compliance (e.g. DTAC), and a clear budget-impact summary.

Engage with NICE early: use NICE’s Office for Market Access or scientific advice services to shape your evidence strategy.

Respond to the consultation: this is the moment to influence how real-world endpoints, learning curves, and implementation costs are treated in HealthTech appraisals.

The bigger picture

This consultation is the clearest move yet toward true parity of esteem between medicines and HealthTech. The evidence bar is rising, but so is the opportunity: a predictable, nationally coordinated route to NHS adoption and reimbursement for technologies that deliver measurable system value.

However, this is likely to apply initially only to a small cohort of technologies in priority areas and some key questions remain unanswered. For example, it’s unclear what the long-term route to market and sustainable reimbursement strategy will be for medtech products that do not fall into prioritised topic areas or are otherwise ineligible for TA. It’s also unclear where funding will be drawn from for medtech products that receive guidance under the revised TA.

Until the new framework is fully established, innovators should treat NICE as a signal generator, considering the HTAs and evidence standards a guide to the evidence, economics, and implementation thresholds that will shape the next phase of NHS medtech procurement.

Disclaimer
This article is for general information only and does not constitute professional advice. It should not be relied upon as the basis for any business, regulatory, or investment decision. Readers should seek appropriate professional or legal advice before taking any action based on this content.